Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Sensei Biotherapeutics ( (SNSE) ) has shared an announcement.
On June 12, 2025, Sensei Biotherapeutics announced a one-for-twenty reverse stock split and a reduction in authorized shares, effective June 16, 2025. This move, approved by stockholders and the board, will adjust stock options and equity plans proportionately, with trading on a split-adjusted basis starting June 17, 2025, on Nasdaq.
The most recent analyst rating on (SNSE) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Sensei Biotherapeutics stock, see the SNSE Stock Forecast page.
Spark’s Take on SNSE Stock
According to Spark, TipRanks’ AI Analyst, SNSE is a Underperform.
Sensei Biotherapeutics faces substantial financial challenges, with no revenue and ongoing net losses. The technical analysis indicates a bearish trend, and the valuation is poor due to negative earnings. However, the positive corporate event regarding trial results offers a glimpse of potential future success. The overall score reflects these mixed factors, with financial weaknesses being the most significant deterrent.
To see Spark’s full report on SNSE stock, click here.
More about Sensei Biotherapeutics
Sensei Biotherapeutics, Inc. operates in the biotherapeutics industry, focusing on the development of innovative immunotherapies for cancer treatment.
Average Trading Volume: 2,720,095
Technical Sentiment Signal: Sell
Current Market Cap: $8.24M
Find detailed analytics on SNSE stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue